BWBin Wu

Bin Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bin Wu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Kefeng Wang

    Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China

    2 shared publications
  • Weiguo Jiang

    Department of Pathology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China

    2 shared publications
  • Xia Wang

    Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China

    2 shared publications
  • Xiaonan Chen

    Department of Urology, Shengjing Hospital of China Medical University, Shenyang, 110004, China

    2 shared publications
  • Xuefeng Liu

    Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China

    2 shared publications
  • Yunhong Zhan

    Department of Urology, Sheng Jing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China

    2 shared publications

Latest Publications

  • miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W

    by Kefeng Wang, Xiaonan Chen, Yunhong Zhan, Weiguo Jiang, Xuefeng Liu, Xia Wang, Bin Wu

    Increasing evidence has demonstrated that small non-coding microRNAs (miRNAs) play important roles in cancer development and progression. Recent studies have shown that microRNA-335 (miR-335) functions as an oncogene or a tumor suppressor in various human cancer types, but its role in clear cell renal cell carcinoma (ccRCC) remains poorly understood. In our study, we firstly found that the expression level of miR-335 was significantly downregulated in ccRCC tissues versus corresponding non-tumor tissues and the low expression of miR-335 was significantly associated with lymph node metastasis, larger tumor size, and poor T stage. Then, we found that overexpression of miR-335 significantly suppressed the proliferation and invasion of 786-O and CaKi-1 ccRCC cell lines. We subsequently found that miR-335 could interact with the 3′-untranslated regions (3′UTR) of B-cell CLL/lymphoma 2 like 2 (BCL-W or BCL2L2) messenger RNA (mRNA) and repress its expression. In addition, re-expression of BCL-W (without the 3′UTR) could partially abrogate the miR-335-induced 786-O and CaKi-1 ccRCC cell proliferation and invasion inhibition. Furthermore, we found that expression patterns of miR-335 were inversely correlated with those of BCL-W mRNA in ccRCC tissues. Taken together, these results indicate that miR-335 acts as a novel tumor suppressor to regulate ccRCC cell proliferation and invasion through downregulation of BCL-W expression.


  • Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma

    by Kefeng Wang, Xiaonan Chen, Yunhong Zhan, Weiguo Jiang, Xuefeng Liu, Xia Wang, Bin Wu

    Aldehyde dehydrogenase 1A1 (ALDH1A1) has been characterized as a cancer stem cell marker in different types of tumors. It plays a key role in various biological processes in tumor, including cell proliferation, invasion and chemoresistance. Recently, ALDH1A1 has been described as a prognostic marker in various tumors. In this study, we detected the expression of ALDH1A1 in 95 clear cell renal cell carcinoma (ccRCC) by immunohistochemistry and correlated it with clinicopathological parameters and prognosis. We further explored the correlation of ALDH1A1 expression to proliferation, invasion and drug sensitivity of renal cancer cell in vitro by silencing of ALDH1A1 in A498 renal cell line. ALDH1A1 protein showed high expression in 53 of 95 cases of ccRCC (56.8 %), which was significantly higher than that in normal tissues (5/23, 21.7 %). ALDH1A1 overexpression was significantly associated with tumor stage (P = 0.000), recurrence (P = 0.000), tumor size (P = 0.000) and vascular invasion (P = 0.023). The Kaplan–Meier survival analysis demonstrated that ALDH1A1 overexpression was significantly associated with shorter recurrence-free survival and overall survival (P = 0.003 and P = 0.008, respectively). Multivariate analysis demonstrated that ALDH1A1 was an independent prognostic factor for patients with ccRCC. Experiments in vitro further showed ALDH1A1 played an essential role in proliferation, invasion and drug sensitivity of renal cancer cell. In conclusion, ALDH1A1 might be a potential molecular marker in ccRCC, which provided us with a new therapeutic target in ccRCC.